Vitamin D and the cardiovascular system

Vitamin D

Volumn , Issue , 2011, Pages 541-563

  Gardner, David G ^a   Chen, Songcang ^a   Glenn, Denis J ^a   Ni, Wei ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878429751     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10031-9     Document Type: Chapter

References (179)

1. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
2. Haussler M.R., Haussler C.A., Bartik L., Whitfield G.K., Hsieh J.C., Slater S., et al. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr. Rev. 2008, 66:S98-112.
3. Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer H.F., et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 2008, 29:726-776.
4. Pilz S., Tomaschitz A., Ritz E., Pieber T.R. Vitamin D status and arterial hypertension: a systematic review. Nat. Rev. Cardiol. 2009, 6:621-630.
5. Merke J., Milde P., Lewicka S., Hugel U., Klaus G., Mangelsdorf D.J., et al. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J. Clin. Invest. 1989, 83:1903-1915.
6. Merke J., Hofmann W., Goldschmidt D., Ritz E. Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif. Tissue Int. 1987, 41:112-114.
7. Suzuki Y., Ichiyama T., Ohsaki A., Hasegawa S., Shiraishi M., Furukawa S. Anti-inflammatory effect of 1 alpha,25-dihydroxyvitamin D(3) in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease. J. Steroid Biochem. Mol. Biol. 2009, 113:134-138.
8. Wong M.S., Delansorne R., Man R.Y., Vanhoutte P.M. Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H289-296.
9. Mitsuhashi T., Morris R.C., Ives H.E. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J. Clin. Invest. 1991, 87:1889-1895.
10. Koh E., Morimoto S., Fukuo K., Itoh K., Hironaka T., Shiraishi T., et al. 1,25-Dihydroxyvitamin D3 binds specifically to rat vascular smooth muscle cells and stimulates their proliferation in vitro. Life Sci. 1988, 42:215-223.
11. Martinesi M., Bruni S., Stio M., Treves C. 1,25-Dihydroxyvitamin D3 inhibits tumor necrosis factor-alpha-induced adhesion molecule expression in endothelial cells. Cell Biol. Int. 2006, 30:365-375.
12. Cardus A., Parisi E., Gallego C., Aldea M., Fernandez E., Valdivielso J.M. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 2006, 69:1377-1384.
13. Koleganova N., Piecha G., Ritz E., Schmitt C.P., Gross M.L. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int. 2009, 75:60-71.
14. Rajasree S., Umashankar P.R., Lal A.V., Sarma P.S., Kartha C.C. 1,25-Dihydroxyvitamin D3 receptor is upregulated in aortic smooth muscle cells during hypervitaminosis D. Life Sci. 2002, 70:1777-1788.
15. Zehnder D., Bland R., Chana R.S., Wheeler D.C., Howie A.J., Williams M.C., et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol. 2002, 13:621-629.
16. Hewison M., Zehnder D., Bland R., Stewart P.M. 1 Alpha-hydroxylase and the action of vitamin D, J. Mol. Endocrinol. 25 2000, 141-148.
17. Somjen D., Weisman Y., Kohen F., Gayer B., Limor R., Sharon O., et al. 25-hydroxyvitamin D3-1 alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005, 111:1666-1671.
18. Wu-Wong J.R., Noonan W., Nakane M., Brooks K.A., Segreti J.A., Polakowski J.S., et al. Vitamin D receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats. Int. J. Endocrinol. 2010, 625852.
19. Karavalakis E., Eraranta A., Vehmas T.I., Koskela J.K., Koobi P., Mustonen J., et al. Paricalcitol treatment and arterial tone in experimental renal insufficiency. Nephron. Exp. Nephrol. 2008, 109:e84-93.
20. Mantell D.J., Owens P.E., Bundred N.J., Mawer E.B., Canfield A.E. 1 Alpha 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ. Res. 2000, 87:214-220.
21. Albert D.M., Scheef E.A., Wang S., Mehraein F., Darjatmoko S.R., Sorenson C.M., et al. Calcitriol is a potent inhibitor of retinal neovascularization, Invest. Ophthalmol. Vis. Sci. 2007, 2327-2334.
22. Furigay P., Swamy N. Anti-endothelial properties of 1,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of calcitriol. J. Steroid Biochem. Mol. Biol. 2004, 89-90:427-431.
23. Chung I., Wong M.K., Flynn G., Yu W.D., Johnson C.S., Trump D.L. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res. 2006, 66:8565-8573.
24. Chung I., Yu W.D., Karpf A.R., Flynn G., Bernardi R.J., Modzelewski R.A., et al. Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironments. J. Steroid Biochem. Mol. Biol. 2007, 103:768-770.
25. Chung I., Han G., Seshadri M., Gillard B.M., Yu W.D., Foster B.A., et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 2009, 69:967-975.
26. Aksoy H., Akcay F., Kurtul N., Baykal O., Avci B. Serum 1,25 dihydroxy vitamin D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. Clin. Biochem. 2000, 33:47-51.
27. Taverna M.J., Sola A., Guyot-Argenton C., Pacher N., Bruzzo F., Slama G., et al. Taq I polymorphism of the vitamin D receptor and risk of severe diabetic retinopathy. Diabetologia 2002, 45:436-442.
28. Talmor Y., Bernheim J., Klein O., Green J., Rashid G. Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 in vitro. Eur. J. Clin. Invest. 2008, 38:548-554.
29. Talmor Y., Golan E., Benchetrit S., Bernheim J., Klein O., Green J., et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am. J. Physiol. Renal. Physiol. 2008, 294:F1059-1064.
30. Equils O., Naiki Y., Shapiro A.M., Michelsen K., Lu D., Adams J., et al. 1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin. Exp. Immunol. 2006, 143:58-64.
31. Hettmannsperger U., Detmar M., Owsianowski M., Tenorio S., Kammler H.J., Orfanos C.E. Cytokine-stimulated human dermal microvascular endothelial cells produce interleukin 6 - inhibition by hydrocortisone, dexamethasone, and calcitriol. J. Invest. Dermatol. 1992, 99:531-536.
32. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7:678-689.
33. Chen S.F. 1 Alpha, 25-dihydroxyvitamin D3 decreased ICAM-1 and ELAM-1 expressions on pulmonary microvascular endothelial cells and neutrophil motivation. J. Steroid Biochem. Mol. Biol. 1995, 52:67-70.
34. Bukoski R.D., DeWan P., McCarron D.A. 1,25 (OH)2 vitamin D3 modifies growth and contractile function of vascular smooth muscle of spontaneously hypertensive rats. Am. J. Hypertens. 1989, 2:553-556.
35. Borges A.C., Feres T., Vianna L.M., Paiva T.B. Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine. Hypertension 1999, 34:897-901.
36. Borges A.C., Feres T., Vianna L.M., Paiva T.B. Recovery of impaired K+ channels in mesenteric arteries from spontaneously hypertensive rats by prolonged treatment with cholecalciferol. Br. J. Pharmacol. 1999, 127:772-778.
37. Kahonen M., Nappi S., Jolma P., Hutri-Kahonen N., Tolvanen J.P., Saha H., et al. Vascular influences of calcium supplementation and vitamin D-induced hypercalcemia in NaCl-hypertensive rats. J. Cardiovasc. Pharmacol. 2003, 42:319-328.
38. Kitagawa S., Yamaguchi Y., Kunitomo M., Imaizumi N., Fujiwara M. Altered vasoconstrictor responsiveness in vitamin D-induced arteriosclerotic rat aortas. Jpn. J. Pharmacol. 1993, 61:283-289.
39. Bian K., Ishibashi K., Bukoski R.D. 1,25(OH)2D3 modulates intracellular Ca2+ and force generation in resistance arteries. Am. J. Physiol. 1996, 270:H230-237.
40. Bukoski R.D., Xue H. On the vascular inotropic action of 1,25-(OH)2 vitamin D3. Am. J. Hypertens. 1993, 6:388-396.
41. Bukoski R.D., Li J., Bo J. Effect of long-term administration of 1,25 (OH)2 vitamin D3 on blood pressure and resistance artery contractility in the spontaneously hypertensive rat. Am. J. Hypertens. 1993, 6:944-950.
42. Shimosawa T., Ando K., Fujita T. Enhancement of vasoconstrictor response by a noncalcemic analogue of vitamin D3. Hypertension 1993, 21:253-258.
43. Tukaj C., Trzonkowski P., Kubasik-Juraniec J., Mysliwski A. Quantifying division of aortal smooth muscle cells in culture stimulated by 1,25(OH)2D3. J. Steroid Biochem. Mol. Biol. 2007, 103:525-528.
44. Yamamoto T., Kozawa O., Tanabe K., Akamatsu S., Matsuno H., Dohi S., et al. 1,25-Dihydroxyvitamin D3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase. Arch. Biochem. Biophys. 2002, 398:1-6.
45. Tanabe K., Tokuda H., Takai S., Matsushima-Nishiwaki R., Hanai Y., Hirade K., et al. Modulation by the steroid/thyroid hormone superfamily of TGF-beta-stimulated VEGF release from vascular smooth muscle cells. J. Cell Biochem. 2006, 99:187-195.
46. Rao R.S., Miano J.M., Olson E.N., Seidel C.L. The A10 cell line: a model for neonatal, neointimal, or differentiated vascular smooth muscle cells?. Cardiovasc. Res. 1997, 36:118-126.
47. Cardus A., Panizo S., Encinas M., Dolcet X., Gallego C., Aldea M., et al. 1,25-Dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009, 204:85-89.
48. Carthy E.P., Yamashita W., Hsu A., Ooi B.S. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 1989, 13:954-959.
49. Wu-Wong J.R., Nakane M., Ma J., Ruan X., Kroeger P.E. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006, 186:20-28.
50. S. Chen, C.S. Law, D.G. Gardner, Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity. J. Steroid Biochem. Mol. Biol. 118:135-141.
51. Noonan W., Koch K., Nakane M., Ma J., Dixon D., Bolin A., et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol. Dial Transplant. 2008, 23:3824-3830.
52. Wu-Wong J.R., Noonan W., Ma J., Dixon D., Nakane M., Bolin A.L., et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J. Pharmacol. Exp. Ther. 2006, 318:90-98.
53. Shioi A., Katagi M., Okuno Y., Mori K., Jono S., Koyama H., et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ. Res. 2002, 91:9-16.
54. X. Li, M.Y. Speer, H. Yang, J. Bergen, C.M. Giachelli, Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin, Arterioscler. Thromb. Vasc. Biol. 30 (2010) 321-326.
55. Valdivielso J.M., Cannata-Andia J., Coll B., Fernandez E. A new role for vitamin D receptor activation in chronic kidney disease. Am. J. Physiol. Renal. Physiol. 2009, 297:F1502-1509.
56. Wu-Wong J.R., Nakane M., Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J. Vasc. Res. 2007, 44:11-18.
57. Wu-Wong J.R., Nakane M., Ma J. Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thromb. Res. 2006, 118:709-714.
58. Wu-Wong J.R., Nakane M., Ma J., Ruan X., Kroeger P.E. VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J. Cell Biochem. 2007, 100:1395-1405.
59. Puri S., Bansal D.D., Uskokovic M.R., MacGregor R.R. Induction of tissue plasminogen activator secretion from rat heart microvascular cells by fM 1,25(OH)(2)D(3). Am. J. Physiol. Endocrinol. Metab. 2000, 278:E293-301.
60. Aihara K., Azuma H., Akaike M., Ikeda Y., Yamashita M., Sudo T., et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J. Biol. Chem. 2004, 279:35798-35802.
61. Beer T.M., Venner P.M., Ryan C.W., Petrylak D.P., Chatta G., Dean Ruether J., et al. High dose calcitriol may reduce thrombosis in cancer patients. Br. J. Haematol. 2006, 135:392-394.
62. Thierry-Palmer M., Cephas S., Sayavongsa P., Doherty A., Arnaud S.B. Dahl salt-sensitive rats develop hypovitaminosis D and hyperparathyroidism when fed a standard diet. Bone 2005, 36:645-653.
63. Thierry-Palmer M., Cephas S., Muttardy F.F., Al-Mahmoud A. High dietary cholecalciferol increases plasma 25-hydroxycholecalciferol concentration, but does not attenuate the hypertension of Dahl salt-sensitive rats fed a high salt diet. J. Steroid Biochem. Mol. Biol. 2008, 111:7-12.
64. Thierry-Palmer M., Carlyle K.S., Williams M.D., Tewolde T., Caines-McKenzie S., Bayorh M.A., et al. Plasma 25-hydroxyvitamin D concentrations are inversely associated with blood pressure of Dahl salt-sensitive rats. J. Steroid Biochem. Mol. Biol. 1998, 66:255-261.
65. Thierry-Palmer M., Tewolde T.K., Forte C., Wang M., Bayorh M.A., Emmett N.L., et al. Plasma 24,25-dihydroxyvitamin D concentration of Dahl salt-sensitive rats decreases during high salt intake. J. Steroid Biochem. Mol. Biol. 2002, 80:315-321.
66. Thierry-Palmer M., Tewolde T.K., Wang M., Carlyle K.S., Forte C., Bayorh M.A., et al. Exogenous 25-hydroxycholecalciferol does not attenuate salt-induced hypertension. J. Steroid Biochem. Mol. Biol. 1998, 67:193-199.
67. Kurtz T.W., Portale A.A., Morris R.C. Evidence for a difference in vitamin D metabolism between spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1986, 8:1015-1020.
68. Lucas P.A., Brown R.C., Drueke T., Lacour B., Metz J.A., McCarron D.A. Abnormal vitamin D metabolism, intestinal calcium transport, and bone calcium status in the spontaneously hypertensive rat compared with its genetic control. J. Clin. Invest. 1986, 78:221-227.
69. Lau K., Langman C.B., Gafter U., Dudeja P.K., Brasitus T.A. Increased calcium absorption in prehypertensive spontaneously hypertensive rat. Role of serum 1,25-dihydroxyvitamin D3 levels and intestinal brush border membrane fluidity. J. Clin. Invest. 1986, 78:1083-1090.
70. DiPette D.J., Greilich P.E., Nickols G.A., Graham G.A., Green A., Cooper C.W., et al. Effect of dietary calcium supplementation on blood pressure and calciotropic hormones in mineralocorticoid-salt hypertension. J. Hypertens. 1990, 8:515-520.
71. Repo J.M., Rantala I.S., Honkanen T.T., Mustonen J.T., Koobi P., Tahvanainen A.M., et al. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int. 2007, 72:977-984.
72. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 2003, 349:446-456.
73. Kuhlmann A., Haas C.S., Gross M.L., Reulbach U., Holzinger M., Schwarz U., et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am. J. Physiol. Renal. Physiol. 2004, 286:F526-533.
74. Koleganova N., Piecha G., Ritz E., Gross M.L. Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol. Dial. Transplant. 2009, 24:778-787.
75. Bodyak N., Ayus J.C., Achinger S., Shivalingappa V., Ke Q., Chen Y.S., et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc. Natl. Acad. Sci. USA 2007, 104:16810-16815.
76. Bukoski R.D., Wang D.B., Wagman D.W. Injection of 1,25-(OH)2 vitamin D3 enhances resistance artery contractile properties. Hypertension 1990, 16:523-531.
77. Mancuso P., Rahman A., Hershey S.D., Dandu L., Nibbelink K.A., Simpson R.U. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J. Cardiovasc. Pharmacol. 2008, 51:559-564.
78. Zhou C., Lu F., Cao K., Xu D., Goltzman D., Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008, 74:170-179.
79. Simpson R.U., Hershey S.H., Nibbelink K.A. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J. Steroid Biochem. Mol. Biol. 2007, 103:521-524.
80. Clowes A.W., Schwartz S.M. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ. Res. 1985, 56:139-145.
81. Lamawansa M.D., Wysocki S.J., House A.K., Norman P.E. Vitamin D3 exacerbates intimal hyperplasia in balloon-injured arteries. Br. J. Surg. 1996, 83:1101-1103.
82. Fishbein G.A., Fishbein M.C. Arteriosclerosis: rethinking the current classification. Arch. Pathol. Lab. Med. 2009, 133:1309-1316.
83. Kitagawa S., Yamaguchi Y., Kunitomo M., Imaizumi N., Fujiwara M. Impairment of endothelium-dependent relaxation in aorta from rats with arteriosclerosis induced by excess vitamin D and a high-cholesterol diet. Jpn. J. Pharmacol. 1992, 59:339-347.
84. Bennani-Kabchi N., Kehel L., el Bouayadi F., Fdhil H., Amarti A., Saidi A., et al. New model of atherosclerosis in sand rats subjected to a high cholesterol diet and vitamin D2. Therapie 1999, 54:559-565.
85. Niederhoffer N., Bobryshev Y.V., Lartaud-Idjouadiene I., Giummelly P., Atkinson J. Aortic calcification produced by vitamin D3 plus nicotine. J. Vasc. Res. 1997, 34:386-398.
86. Henrion D., Chillon J.M., Godeau G., Muller F., Capdeville-Atkinson C., Hoffman M., et al. The consequences of aortic calcium overload following vitamin D3 plus nicotine treatment in young rats. J. Hypertens. 1991, 9:919-926.
87. Ventura H.O., Mehra M.R., Smart F.W., Stapleton D.D. Cardiac allograft vasculopathy: current concepts. Am. Heart J. 1995, 129:791-799.
88. Libby P., Zhao D.X. Allograft arteriosclerosis and immune-driven angiogenesis. Circulation 2003, 107:1237-1239.
89. Raisanen-Sokolowski A.K., Pakkala I.S., Samila S.P., Binderup L., Hayry P.J., Pakkala S.T. A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation 1997, 63:936-941.
90. Mathew S., Lund R.J., Chaudhary L.R., Geurs T., Hruska K.A. Vitamin D receptor activators can protect against vascular calcification. J. Am. Soc. Nephrol. 2008, 19:1509-1519.
91. Nibbelink K.A., Tishkoff D.X., Hershey S.D., Rahman A., Simpson R.U. 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J. Steroid Biochem. Mol. Biol. 2007, 103:533-537.
92. O'Connell T.D., Simpson R.U. Immunochemical identification of the 1,25-dihydroxyvitamin D3 receptor protein in human heart. Cell Biol. Int. 1996, 20:621-624.
93. Simpson R.U., Thomas G.A., Arnold A.J. Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J. Biol. Chem. 1985, 260:8882-8891.
94. Tishkoff D.X., Nibbelink K.A., Holmberg K.H., Dandu L., Simpson R.U. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 2008, 149:558-564.
95. Walters M.R., Wicker D.C., Riggle P.C. 1,25-Dihydroxyvitamin D3 receptors identified in the rat heart. J. Mol. Cell Cardiol. 1986, 18:67-72.
96. Chen S., Glenn D.J., Ni W., Grigsby C.L., Olsen K., Nishimoto M., et al. Expression of the vitamin D receptor is increased in the hypertrophic heart. Hypertension 2008, 52:1106-1112.
97. Wang G.F., Nikovits W., Schleinitz M., Stockdale F.E. A positive GATA element and a negative vitamin D receptor-like element control atrial chamber-specific expression of a slow myosin heavy-chain gene during cardiac morphogenesis. Mol. Cell. Biol. 1998, 18:6023-6034.
98. Wang G.F., Nikovits W., Bao Z.Z., Stockdale F.E. Irx4 forms an inhibitory complex with the vitamin D and retinoic X receptors to regulate cardiac chamber-specific slow MyHC3 expression. J. Biol. Chem. 2001, 276:28835-28841.
99. Zeller R., Bloch K.D., Williams B.S., Arceci R.J., Seidman C.E. Localized expression of the atrial natriuretic factor gene during cardiac embryogenesis. Genes Dev. 1987, 1:693-698.
100. Evans D., Miller J.B., Stockdale F.E. Developmental patterns of expression and coexpression of myosin heavy chains in atria and ventricles of the avian heart. Dev. Biol. 1988, 127:376-383.
101. Wang G.F., Nikovits W., Schleinitz M., Stockdale F.E. Atrial chamber-specific expression of the slow myosin heavy chain 3 gene in the embryonic heart. J. Biol. Chem. 1996, 271:19836-19845.
102. Chen S., Wu J., Hsieh J.C., Whitfield G.K., Jurutka P.W., Haussler M.R., et al. Suppression of ANP gene transcription by liganded vitamin D receptor: involvement of specific receptor domains. Hypertension 1998, 31:1338-1342.
103. Chien K.R., Zhu H., Knowlton K.U., Miller-Hance W., van-Bilsen M., O'Brien T.X., et al. Transcriptional regulation during cardiac growth and development. Annu. Rev. Physiol. 1993, 55:77-95.
104. Wu J., Garami M., Cao L., Li Q., Gardner D.G. 1,25(OH)2D3 suppresses expression and secretion of atrial natriuretic peptide from cardiac myocytes. Am. J. Physiol. 1995, 268:E1108-1113.
105. Wu J., Garami M., Cheng T., Gardner D.G. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J. Clin. Invest. 1996, 97:1577-1588.
106. Chen S., Costa C.H., Nakamura K., Ribeiro R.C., Gardner D.G. Vitamin D-dependent suppression of human atrial natriuretic peptide gene promoter activity requires heterodimer assembly. J. Biol. Chem. 1999, 274:11260-11266.
107. Chen S., Cui J., Nakamura K., Ribeiro R.C., West B.L., Gardner D.G. Coactivator-vitamin D receptor interactions mediate inhibition of the atrial natriuretic peptide promoter. J. Biol. Chem. 2000, 275:15039-15048.
108. Weishaar R.E., Simpson R.U. Vitamin D3 and cardiovascular function in rats. J. Clin. Invest. 1987, 79:1706-1712.
109. Weishaar R.E., Kim S.N., Saunders D.E., Simpson R.U. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am. J. Physiol. 1990, 258:E134-142.
110. O'Connell T.D., Simpson R.U. 1,25-Dihydroxyvitamin D3 regulation of myocardial growth and c-myc levels in the rat heart. Biochem. Biophys. Res. Commun. 1995, 213:59-65.
111. O. Gezmish, M. Tare, H.C. Parkington, R. Morley, E.R. Porrello, K.J. Bubb, et al., Maternal vitamin D deficiency leads to cardiac hypertrophy in rat offspring, Reprod. Sci. 17 (2010) 168-176.
112. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
113. Xiang W., Kong J., Chen S., Cao L.P., Qiao G., Zheng W., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E125-132.
114. Yuan W., Pan W., Kong J., Zheng W., Szeto F.L., Wong K.E., et al. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem. 2007, 282:29821-29830.
115. G. Zhao, R.U. Simpson, Interaction between vitamin D receptor with caveolin-3 and regulation by 1,25-dihydroxyvitamin D(3) in adult rat cardiomyocytes. J. Steroid Biochem. Mol. Biol.
116. Weber K.T., Weglicki W.B., Simpson R.U. Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium. Cardiovasc. Res. 2009, 81:500-508.
117. Berk B.C., Fujiwara K., Lehoux S. ECM remodeling in hypertensive heart disease. J. Clin Invest. 2007, 117:568-575.
118. Rahman A., Hershey S., Ahmed S., Nibbelink K., Simpson R.U. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J. Steroid Biochem. Mol. Biol. 2007, 103:416-419.
119. Timms P.M., Mannan N., Hitman G.A., Noonan K., Mills P.G., Syndercombe-Court D., et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?. QJM 2002, 95:787-796.
120. Uysal S., Kalayci A.G., Baysal K. Cardiac functions in children with vitamin D deficiency rickets. Pediatr. Cardiol. 1999, 20:283-286.
121. Przybylski R., McCune S., Hollis B., Simpson R.U. Vitamin D deficiency in the spontaneously hypertensive heart failure [SHHF] prone rat. Nutr. Metab. Cardiovasc. Dis. 2009.
122. M. Mizobuchi, H. Nakamura, M. Tokumoto, J. Finch, J. Morrissey, H. Liapis, et al., Myocardial effects of VDR activators in renal failure, J. Steroid Biochem. Mol. Biol. 121 (2010) 188-192.
123. Yee Y.K., Chintalacharuvu S.R., Lu J., Nagpal S. Vitamin D receptor modulators for inflammation and cancer. Mini. Rev. Med. Chem. 2005, 5:761-778.
124. Y. Zhang, J. Kong, D.K. Deb, A. Chang, Y.C. Li, Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system, J. Am. Soc. Nephrol. 21 (2010) 966-973.
125. Szalay G., Sauter M., Haberland M., Zuegel U., Steinmeyer A., Kandolf R., et al. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ. Res. 2009, 104:851-859.
126. Rostand S.G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997, 30:150-156.
127. Forman J.P., Giovannucci E., Holmes M.D., Bischoff-Ferrari H.A., Tworoger S.S., Willett W.C., et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49:1063-1069.
128. Forman J.P., Curhan G.C., Taylor E.N. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008, 52:828-832.
129. Snijder M.B., Lips P., Seidell J.C., Visser M., Deeg D.J., Dekker J.M., et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J. Intern. Med. 2007, 261:558-565.
130. Reis J.P., von Muhlen D., Kritz-Silverstein D., Wingard D.L., Barrett-Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007, 30:1549-1555.
131. Argiles A., Lorho R., Servel M.F., Couret I., Chong G., Mourad G. Blood pressure is correlated with vitamin D(3) serum levels in dialysis patients. Blood Purif. 2002, 20:370-375.
132. Muray S., Parisi E., Cardus A., Craver L., Fernandez E. Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. J. Hypertens. 2003, 21:2069-2075.
133. Brickman A.S., Stern N., Sowers J.R. Circadian variations of catecholamines and blood pressure in patients with pseudohypoparathyroidism and hypertension. Chronobiologia 1990, 17:37-44.
134. Pilz S., Tomaschitz A., Ritz E., Pieber T.R. Vitamin D status and arterial hypertension: a systematic review. Nat. Rev. Cardiol. 2009.
135. Pittas A.G., Chung M., Trikalinos T., Mitri J., Brendel M., Patel K., et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann. Intern. Med. 2010, 152:307-314.
136. Forouhi N.G., Luan J., Cooper A., Boucher B.J., Wareham N.J. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008, 57:2619-2625.
137. R. Jorde, Y. Figenschau, N. Emaus, M. Hutchinson, G. Grimnes, Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension, Hypertension 55 (2010) 792-798.
138. Wang L., Manson J.E., Buring J.E., Lee I.M., Sesso H.D. Dietary Intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women, Hypertension 2008, 1073-1079.
139. Pfeifer M., Begerow B., Minne H.W., Nachtigall D., Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 2001, 86:1633-1637.
140. Krause R., Buhring M., Hopfenmuller W., Holick M.F., Sharma A.M. Ultraviolet B and blood pressure. Lancet 1998, 352:709-710.
141. Margolis K.L., Ray R.M., Van Horn L., Manson J.E., Allison M.A., Black H.R., et al. Effect of calcium and vitamin D supplementation on blood pressure the Women's Health Initiative randomized trial. Hypertension 2008, 52:847-855.
142. Geleijnse J.M. Vitamin D and hypertension: does the Women's Health Initiative solve the question?. Hypertension 2008, 52:803-804.
143. Reis J.P., Michos E.D., von Muhlen D., Miller E.R. Differences in vitamin D status as a possible contributor to the racial disparity in peripheral arterial disease. Am. J. Clin. Nutr. 2008, 88:1469-1477.
144. Fahrleitner A., Dobnig H., Obernosterer A., Pilger E., Leb G., Weber K., et al. Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease. J. Gen. Intern. Med. 2002, 17:663-669.
145. Melamed M.L., Michos E.D., Post W., Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 2008, 168:1629-1637.
146. Bostick R.M., Kushi L.H., Wu Y., Meyer K.A., Sellers T.A., Folsom A.R. Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am. J. Epidemiol. 1999, 149:151-161.
147. Trivedi D.P., Doll R., Khaw K.T. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003, 326:469.
148. Prince R.L., Austin N., Devine A., Dick I.M., Bruce D., Zhu K. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch. Intern. Med. 2008, 168:103-108.
149. Hsia J., Heiss G., Ren H., Allison M., Dolan N.C., Greenland P., et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007, 115:846-854.
150. Maiya S., Sullivan I., Allgrove J., Yates R., Malone M., Brain C., et al. Hypocalcaemia and vitamin D deficiency: an important, but preventable, cause of life-threatening infant heart failure. Heart 2008, 94:581-584.
151. Amirlak I., Al Dhaheri W., Narchi H. Dilated cardiomyopathy secondary to nutritional rickets. Ann. Trop. Paediatr. 2008, 28:227-230.
152. Kim B.G., Chang S.K., Kim S.M., Hwang J.S., Jung J.W. Dilated cardiomyopathy in a 2 month-old infant: a severe form of hypocalcemia with vitamin D deficient rickets. Korean Circ. J. 2010, 40:201-203.
153. Dobnig H., Pilz S., Scharnagl H., Renner W., Seelhorst U., Wellnitz B., et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 2008, 168:1340-1349.
154. Kim D.H., Sabour S., Sagar U.N., Adams S., Whellan D.J. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am. J. Cardiol. 2008, 102:1540-1544.
155. Pilz S., Marz W., Wellnitz B., Seelhorst U., Fahrleitner-Pammer A., Dimai H.P., et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J. Clin. Endocrinol. Metab. 2008, 93:3927-3935.
156. Wilke R.A., Simpson R.U., Mukesh B.N., Bhupathi S.V., Dart R.A., Ghebranious N.R., et al. Genetic variation in CYP27B1 is associated with congestive heart failure in patients with hypertension. Pharmacogenomics 2009, 10:1789-1797.
157. Witte K.K., Nikitin N.P., Parker A.C., von Haehling S., Volk H.D., Anker S.D., et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur. Heart. J. 2005, 26:2238-2244.
158. Witham M.D., Crighton L.J., Gillespie N.D., Struthers A.D., McMurdo M.E. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ. Heart Fail. 2010, 3:195-201.
159. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 2006, 83:754-759.
160. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007, 71:31-38.
161. Wolf M., Shah A., Gutierrez O., Ankers E., Monroy M., Tamez H., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007, 72:1004-1013.
162. Wolf M., Thadhani R. Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J. Steroid Biochem. Mol. Biol. 2007, 103:487-490.
163. Weiner D.E., Tighiouart H., Amin M.G., Stark P.C., MacLeod B., Griffith J.L., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol. 2004, 15:1307-1315.
164. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351:1296-1305.
165. Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernan M.A., Camargo C.A., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 2005, 16:1115-1125.
166. Shoji T., Shinohara K., Kimoto E., Emoto M., Tahara H., Koyama H., et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial. Transplant. 2004, 19:179-184.
167. Mehrotra R., Kermah D.A., Salusky I.B., Wolf M.S., Thadhani R.I., Chiu Y.W., et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009, 76:977-983.
168. Shoben A.B., Rudser K.D., de Boer I.H., Young B., Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J. Am. Soc. Nephrol. 2008, 19:1613-1619.
169. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch. Intern. Med. 2008, 168:397-403.
170. Goldsmith D.J., Covic A., Sambrook P.A., Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron. Exp. Nephrol. 1997, 77:37-43.
171. Raggi P., Boulay A., Chasan-Taber S., Amin N., Dillon M., Burke S.K., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J. Am. Coll. Cardiol. 2002, 39:695-701.
172. Querfeld U., Mak R.H. Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr. Nephrol. 2010.
173. Tentori F., Hunt W.C., Stidley C.A., Rohrscheib M.R., Bedrick E.J., Meyer K.B., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006, 70:1858-1865.
174. Palmer S.C., McGregor D.O., Macaskill P., Craig J.C., Elder G.J., Strippoli G.F. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann. Intern. Med. 2007, 147:840-853.
175. Knekt P., Laaksonen M., Mattila C., Harkanen T., Marniemi J., Heliovaara M., et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008, 19:666-671.
176. Liu S., Song Y., Ford E.S., Manson J.E., Buring J.E., Ridker P.M. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005, 28:2926-2932.
177. Pittas A.G., Dawson-Hughes B., Li T., Van Dam R.M., Willett W.C., Manson J.E., et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006, 29:650-656.
178. Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2007, 92:2017-2029.
179. von Hurst P.R., Stonehouse W., Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br. J. Nutr. 2010, 103:549-555.